endomorphin-2 and Chronic-Disease

endomorphin-2 has been researched along with Chronic-Disease* in 2 studies

Reviews

1 review(s) available for endomorphin-2 and Chronic-Disease

ArticleYear
Endomorphins as agents for the treatment of chronic inflammatory disease.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2006, Volume: 20, Issue:3

    Endomorphin (EM)-1 and EM-2 are tetrapeptides located within the mammalian central nervous system and immune tissues, with high affinity and specificity for micro-opioid receptors. Most of the literature has focused on the analgesic properties of EM-1 and EM-2 in animal models of neuropathic or neurogenic pain, but there is persuasive evidence emerging that EMs can also exert potent anti-inflammatory effects in both acute and chronic peripheral inflammation. The purpose of this review is to present and evaluate the evidence for anti-inflammatory properties of EM-1 and EM-2 with a view to their potential for use in chronic human inflammatory disease. Distribution of EMs within the immune system and functional roles as immunomodulatory agents are summarized and discussed. Possible milestones to be met revolve around issues of peptide stability, biodegradability problems and optimal route and method of delivery. The potential for delivery of a low-cost drug with both peripheral anti-inflammatory and analgesic properties, effective in low doses, and targeted to the site of inflammation, should focus our attention on further development of EMs as potent therapeutic agents in chronic inflammation.

    Topics: Animals; Chronic Disease; Humans; Inflammation; Oligopeptides; Receptors, Opioid, mu

2006

Other Studies

1 other study(ies) available for endomorphin-2 and Chronic-Disease

ArticleYear
Decreases in endomorphin-2-like immunoreactivity concomitant with chronic pain after nerve injury.
    Neuroscience, 2001, Volume: 105, Issue:3

    Nerve injury often leads to chronic, sometimes excruciating, pain. The mechanisms contributing to this syndrome include neurochemical plasticity in neurons involved in the earliest stages of pain transmission. Endomorphin-2 (Tyr-Pro-Phe-Phe-NH(2)) is an endogenous morphine-like substance that binds to the mu-opioid receptor with high affinity and selectivity. Endomorphin-2-like immunoreactivity (LI) is present in the superficial layers of the dorsal horn in the spinal cord and in primary afferents, suggesting a role for this peptide in pain transmission. To determine whether spinal endomorphin-2-LI is altered in an animal model of chronic pain, the left sciatic nerve of Swiss Webster and ICR mice was ligated in a modified Seltzer model of nerve injury. Changes in endomorphin-2-LI were assessed by immunocytochemistry at 2, 4 and 14 days after nerve injury. The side of the spinal cord ipsilateral to the nerve injury exhibited a dramatic decrease in endomorphin-2-LI relative to the contralateral side and to control animals. The change was restricted to the medial dorsal horn in the lumbar segments innervated by the sciatic nerve. Substance P-LI showed a small decrease, while calcitonin gene-related peptide-LI was unchanged. Both thermal hyperalgesia, as evidenced by significantly decreased paw withdrawal latencies, and decreased endomorphin-2-LI were observed within 2 days of injury and were most pronounced at 2 weeks after injury. The decrease in endomorphin-2-LI during the development of chronic pain is consistent with the loss of an inhibitory influence on pain transmission. These results provide the first evidence that reduction of an endogenous opioid in primary afferents is associated with injury-induced chronic pain.

    Topics: Animals; Calcitonin Gene-Related Peptide; Chronic Disease; Down-Regulation; Functional Laterality; Hyperalgesia; Immunohistochemistry; Ligation; Male; Mice; Mice, Inbred ICR; Nerve Crush; Neuralgia; Oligopeptides; Pain Measurement; Pain Threshold; Peripheral Nervous System Diseases; Posterior Horn Cells; Reaction Time; Sciatic Nerve; Substance P

2001